Growth Hormone Mitigates against Lethal Irradiation and Enhances Hematologic and Immune Recovery in Mice and Nonhuman Primates
Benny J. Chen(Duke University), Nelson J. Chao(Duke University), Kouros Owzar(Duke University), Pamela Daher(Duke Medical Center), Garrett G. Muramoto(Duke Medical Center), J. Mark Cline(Wake Forest University), Divino Deoliveira(Duke Medical Center), Sarah K. Meadows(HudsonAlpha Institute for Biotechnology), J. Daniel Bourland(Wake Forest University), John P. Chute(Cedars-Sinai Medical Center), Gregory D. Sempowski(Duke University), Ivan Spasojević(Duke University), Xiaojuan Wang(Duke Medical Center), Greg Dugan(Wake Forest University), Chen Jiang, Diane Gesty‐Palmer(BioCryst Pharmaceuticals (United States))
Cited by 59
Related Papers
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
|The Lancet|2009|1.4k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation
|New England Journal of Medicine|2020|739
Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group
|Journal of Clinical Oncology|2008|655
Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research
|Biology of Blood and Marrow Transplantation|2014|442